Clinical Trials Browser

Disease Progression × axicabtagene ciloleucel × 90 days × Clear all

NCT04205838 2026-02-27

Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

Phase 2 Terminated

Lymphoma, Large B-Cell, Diffuse, Disease Progression